Candel Therapeutics Secures $130M for Lead Prostate Cancer Program

Candel Therapeutics has secured a $130 million term loan facility with Trinity Capital to fund its lead program, CAN-2409, in prostate cancer. The non-dilutive funding will support operational priorities, including the planned BLA submission and commercialization efforts. The company is also advancing a program in therapy-resistant non-small cell lung cancer. The deal provides strong external validation and allows for structured access to funds upon meeting certain milestones. Candel has prioritized prostate cancer and non-small cell lung cancer programs, pausing the launch of a pancreatic cancer program due to the need for additional non-dilutive funding or a strategic partnership.

Candel Therapeutics, Inc. (NASDAQ:CADL) has secured a significant financial boost with the announcement of a five-year, $130 million term loan facility with Trinity Capital. The deal, which was finalized on Tuesday, will provide non-dilutive funding to support the company's operational priorities, including the planned Biologics License Application (BLA) submission for its lead asset, CAN-2409, in prostate cancer, as reported by a Seeking Alpha article.

The term loan facility is structured with four tranches, starting with an initial $50 million available for immediate drawdown upon closing, followed by two $50 million tranches that are subject to the achievement of certain regulatory, clinical, and operational milestones. The final tranche of $30 million is available at the lender’s discretion.

Dr. Paul Peter Tak, CEO of Candel Therapeutics, explained that the non-dilutive funding is crucial for supporting the company's key operational priorities. The primary focus is on the BLA submission for CAN-2409 and completing the commercialization efforts. Additionally, the funding will enable the company to advance its therapy-resistant non-small cell lung cancer program, which has shown encouraging data, according to a Proactive Investors article.

Candel Therapeutics has prioritized its prostate cancer and non-small cell lung cancer programs, pausing the launch of a large clinical program in pancreatic cancer due to the need for additional non-dilutive funding or a strategic partnership. The company is actively exploring potential partners and has had ongoing, confidential discussions with several entities, the Proactive Investors piece noted.

The deal with Trinity Capital provides strong external validation and allows Candel Therapeutics to draw down funds as needed, rather than borrowing the entire amount at once. This structured approach aligns with the company's strategic goals and ensures that it can manage its cash flow effectively, the Seeking Alpha article added.

In conclusion, Candel Therapeutics' $130 million term loan facility with Trinity Capital is a significant milestone in the company's quest to bring innovative cancer therapies to market. The non-dilutive funding will support its lead program in prostate cancer and other critical initiatives, positioning the company for future growth and success.